Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of
cancer, and tools to improve genetic screening rates across the healthcare system
Counsyl, a DNA testing and genetic counseling service, today announced its expansion into the oncology market, with a focus on advancing cancer risk screening and helping cancer prevention efforts.
Counsyl’s launch in this market includes:
“In the US, it’s estimated that almost five million people have a hereditary cancer mutation. In some cases, that means facing up to an 80% lifetime risk for cancer,” said Ramji Srinivasan, Counsyl Cofounder and CEO. “Inherited cancer remains a considerable, unknown risk for so many individuals and families who would benefit from this knowledge. Our goal is to help people understand their cancer risk by expanding access to genetic screening, providing on-demand genetic counseling, and creating tools, like FirstCare, that benefit both physicians and their patients.”
Inherited Cancer Screen results provided by Counsyl help physicians identify patients who may benefit from more aggressive screening procedures, changes in lifestyle or medication regimens, or preventative actions such as surgery. To help inform these decisions, Counsyl provides physician and patient access to a team of more than 40 board-certified genetic counselors.
Counsyl believes that low genetic testing rates among patients who are eligible is, in part, due to difficulty collecting and assessing a patient’s family history, and was inspired to develop and pilot FirstCare, a new software tool to assist physicians.
Robert Altman, M.D., Chair, Department of Obstetrics & Gynecology, Sutter Gould Medical Foundation said of this new tool, “Patients complete a brief, comprehensive electronic assessment, allowing for more efficient and effective identification of people at a high risk for hereditary cancer. They can then be appropriately counseled and tested. Patients who screen positive for hereditary cancer germline mutations can be more closely monitored, and receive therapeutic interventions designed to reduce their risk of developing cancer.”
Counsyl is announcing this news in advance of its exhibition at the American Society of Clinical Oncology (ASCO) Annual Meeting June 3 – 7, 2016 in Chicago, Illinois at McCormick Place. Visit the Counsyl booth, #2075, June 4 – 6, 2016, 9:00AM – 5:00PM.
Counsyl is a DNA testing and genetic counseling service. We’re committed to helping patients understand their DNA and how it can inform important health decisions. Whether it’s starting a family or evaluating risk for cancer, Counsyl’s DNA tests provide patients with early awareness about genetic conditions, so they can live informed and prepare for the future. Counsyl has screened more than 600,000 patients and served more than 10,000 health care professionals. For more information, visit www.counsyl.com.
Source: Counsyl press release.
Copyright © 2019 CancerConnect. All Rights Reserved.
Tags: asco, ASCO16, ASCO2016, BRCAtesting, breast, Breast Cancer, breastcancerawareness, Colon, Colon Cancer, DNAtesting, genetic testing, inherited cancer screen, Melanoma, News Tips and Features, News Tips and Features Other, ovarian, Ovarian Cancer, pancreatic, Pancreatic Cancer, prostate, Prostate Cancer, Screening/Prevention Breast Cancer, Screening/Prevention Colon Cancer, Screening/Prevention Melanoma, Screening/Prevention Ovarian Cancer, Screening/Prevention Pancreatic Cancer, Screening/Prevention Prostate Cancer